Exercise performance and metabolism Nutritional, Metabolic, Endocrine
Conditions
Interventions
The study will be a 2-month double-blind, randomised, placebo-controlled crossover intervention trial in endurance-trained males.
All participants will complete the treatment (probiotic supplement)
1 B Lactobacillus rhamnosus LC-705 for the first 12 days of the 14-day supplementation period (in 1 capsule/day), and 15B Propionibacterium
5B Lactobacillus rhamnosus LC-705 for the last 2 days of the 14-day supplementation period (in 5 capsules/day).
Supplementation of placebo (taste and appearance matched): Capsule containing maltodext
blood lactate concentration of 4mmol/L). At rest (pre), following the submaximal exercise test (during), and following the exercise performance trial (post), saliva (salivary IgA, cortisol) and venou
Sponsors
Nottingham Trent University
Eligibility
Sex/Gender
Male
Age
20 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1. Male 2. Aged between 20-40 years 3. Physically active and defined as “trained” in line with McKay et al. (2022) 4. Have a 5km time trial personal best of <21 minutes within the last three months
Exclusion criteria
Exclusion criteria: 1. Routine consumption of ?-3 PUFA supplements and/or supplements with antioxidants 2. Routine consumption of prebiotic, and/or probiotic supplements 3. Routine consumption of collagen-based supplements 4. Use of antibiotics in the past 3 months 5. Milk allergy or lactose intolerance 6. Take a daily dose of aspirin or other NSAIDs 7. Intake of drugs which affect gastrointestinal mobility/laxatives in the 4 weeks before the study 8. Previously diagnosed with COPD, emphysema, chronic bronchitis or similar respiratory illness 9. History of heart failure, pulmonary hypertension, embolism, or other pulmonary heart disease 10. History of recurrent chest infections 11. Smoker 12. Acute infection within the last four weeks 13. Major operation within the past four months 14. History of gastrointestinal drug reaction 15. History or current evidence of gastrointestinal disease, e.g. chronic constipation, diarrhoea, irritable bowel syndrome, Crohn’s Disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Venous propionate measured using gas chromatography–mass spectrometry at pre and post intervention | — |
Secondary
| Measure | Time frame |
|---|---|
| Venous intestinal-fatty acid binding protein measured using enzyme-linked immunosorbent assay at pre and post intervention;Venous lipopolysaccharide binding protein measured using enzyme-linked immunosorbent assay at pre and post intervention;Venous testosterone measured using enzyme-linked immunosorbent assay at pre and post intervention;Salivary immunoglobulin A measured using enzyme-linked immunosorbent assay at pre and post intervention;Salivary cortisol measured using enzyme-linked immunosorbent assay at pre and post intervention;Gut microbiome composition measured using DNA extraction and shotgun metagenomics at pre and post intervention;Faecal short chain fatty acids measured using gas chromatography–mass spectrometry at pre and post intervention;Blood lactate measured using a biosen at pre and post intervention during a submaximal exercise test;Rating of perceived effort measured using the Borg (6-20) scale at pre and post intervention during exercise trials;Gastrointestinal symptoms measured using modified Visual Analogue Scale (VAS; Gaskell & Snipe, 2019) at pre and post intervention during exercise trials;Exercise performance measured using self-paced 5km time trial at pre and post intervention;Sleep quality measured using the Pittsburgh Sleep Quality Index (PSQI) at weekly intervals during supplementation period;Exercise recovery measured using the Recovery-Stress Questionnaire for Athletes (RSQA-Sport) at weekly intervals during supplementation period;Gastrointestinal discomfort measured using the Gastrointestinal Symptom Rating Scale (GSRS) at weekly intervals during supplementation period and during exercise trials;Common cold symptoms measured using the Jackson Cold Scale (JCS) questionnaire at daily intervals during supplementation period | — |
Countries
England, United Kingdom
Contacts
Public ContactNeil Williams
Outcome results
None listed